ArticleTherapeutic advances in neurological disorders2023

Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study.

Alasdair J Coles et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.